BTIG Sees Valeant's (VRX) Growth Plan Taking Longer than Expected to Implement; Affirms at 'Neutral' (WBA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
UPDATE: Valeant's (VRX) Plaque Psoriasis Injection Faces July 19th FDA Panel
June 9, 2016 9:14 AM EDT(Updated - June 9, 2016 9:19 AM EDT)
Valeant Pharma's (NYSE: VRX) plaque psoriasis injection faces July 19th FDA panel, according to Bloomberg.
UPDATE - The HHS document is embedded below:
... MoreValeant (VRX) PT Cut to $11 at Mizuho
June 8, 2016 2:23 PM EDTMizuho Securities analyst Irina Koffler reiterated an Underperform rating on Valeant Pharmaceuticals (NYSE: VRX) and cut her price target to $11.00 (from $18.00), saying she is not convinced of a turnaround.
Koffler commented, "Valeant lowered 2016 guidance for the second time this year.... More
Valeant (VRX) Said Near Agreement on Asset Sales - Source
June 8, 2016 1:40 PM EDTValeant (NYSE: VRX) is nearing an agreement to sell its Latin American operations, according to a source claiming to have knowledge of the situation. There is also a possibility Valeant could decide to divest Salix, the person said.
If the latter scenario is true and... More
Valeant Pharma (VRX) Said to Try Restructuring Walgreens (WBA) Pact - FT
June 8, 2016 11:02 AM EDT(Updated)
Valeant Pharma (NYSE: VRX) is attempting to restructure its agreement with Walgreens (Nasdaq: WBA) after warning that it is losing money, according to the Financial Times. Valeant will consider terminating the agreement within months unless the situation improves, the report said.
... MoreValeant Pharmaceuticals (VRX): Dermatology Is Losing Money - Jefferies
June 8, 2016 8:50 AM EDTJefferies analyst, David Steinberg, cut his PT on Valeant Pharmaceuticals (NYSE: VRX) to meet lowered guidance. Q1 revs exceeded consensus by ~$20M while EPS was $0.09 below consensus though both were within mgts guidance range. With a new CEO in place, VRX not surprisingly significantly... More
Valeant (VRX) PT Cut to $33 at RBC Capital
June 8, 2016 7:07 AM EDTRBC Capital analyst Douglas Miehm lowered estimate and his price target on Sector Perform-rated Valeant Pharmaceuticals (NYSE: VRX) to $33.00 (from $58.00) following mixed earnings, which were overshadowed by sharply lower guidance.
Miehm commented, "Total revenue guidance was lowered to $9.9-10.1B, from $11.0-11.2B and cash EPS guidance... More
Valeant (VRX) PT Cut to $38 at BMO Capital
June 8, 2016 6:27 AM EDTBMO Capital analyst Alex Arfaei reiterated a Market Perform rating and cut his price target on Valeant Pharmaceuticals (NYSE: VRX) to $38.00 (from $44.00) after the company cut guidance. While the firm expected the cut, it was greater than they and the market expected.
Arfaei commented, "Although we expected Valeant to lower its guidance, the magnitude of the downward revision was greater than we and the market expected. This... More
